Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-015610
Filing Date
2025-04-25
Accepted
2025-04-25 09:00:45
Documents
23
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20041194x1_def14a.htm   iXBRL DEF 14A 991454
6 logo_pmvpharma.jpg GRAPHIC 55635
7 ny20041194x1_pc01.jpg GRAPHIC 603773
8 ny20041194x1_pc02.jpg GRAPHIC 463375
9 ny20041194x1_pvpchart01.jpg GRAPHIC 152896
10 ny20041194x1_pvpchart02.jpg GRAPHIC 127733
11 sig_davidhmack.jpg GRAPHIC 15618
12 sig_robertticktin.jpg GRAPHIC 17857
  Complete submission text file 0001140361-25-015610.txt   5388996

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA pmvp-20250605.xsd EX-101.SCH 4017
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE pmvp-20250605_def.xml EX-101.DEF 3124
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE pmvp-20250605_lab.xml EX-101.LAB 7071
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE pmvp-20250605_pre.xml EX-101.PRE 9094
25 EXTRACTED XBRL INSTANCE DOCUMENT ny20041194x1_def14a_htm.xml XML 186762
Mailing Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540
Business Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540 (609) 642-6670
PMV Pharmaceuticals, Inc. (Filer) CIK: 0001699382 (see all company filings)

EIN.: 463218129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39539 | Film No.: 25870182
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)